Abstract Number: 0579 • ACR Convergence 2020
Risk Factors of Nonadherence in New Rheumatoid Arthritis Patients
Background/Purpose: Biologic disease-modifying antirheumatic drug (bDMARD) therapies are commonly prescribed for rheumatoid arthritis (RA) treatment. However, their high out-of-pocket (OOP) cost may limit patient access…Abstract Number: 0805 • ACR Convergence 2020
The PROPER Study: Results of the First Interim Analysis of a Pan-EU Real-World Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis
Background/Purpose: SB5, an adalimumab biosimilar received EU marketing authorisation in August 2017, based on the totality of evidence from pre-clinical and clinical Phase I and…Abstract Number: 0880 • ACR Convergence 2020
Ixekizumab Improves Signs and Symptoms of Patients with Radiographic and Non-radiographic Axial Spondyloarthritis and Extra-articular Manifestation of Enthesitis Through 16 Weeks
Background/Purpose: Axial SpA (axSpA) is a chronic inflammatory disease affecting the spine and sacroiliac (SI) joints and has two subtypes that represent the spectrum of…Abstract Number: 1009 • ACR Convergence 2020
Missing Data and Multiple Imputation in Rheumatoid Arthritis Registries Using Sequential Random Forest Method
Background/Purpose: Missing data in clinical epidemiological researches violate the intention to treat principle, reduce statistical power and can induce bias if they are related to…Abstract Number: 1347 • ACR Convergence 2020
Predictors of Response in Patients with Non-Radiographic Axial Spondyloarthritis Receiving Certolizumab Pegol in the C-axSpAnd Study
Background/Purpose: Identification of predictive clinical factors of long-term treatment response in non-radiographic axial spondyloarthritis (nr-axSpA) may contribute to improved management of patients with this chronic…Abstract Number: 1477 • ACR Convergence 2020
Adherence in Patients with Chronic Rheumatic Diseases Treated with Biological and Synthetic Targeted Therapies During COVID-19 Pandemic
Background/Purpose: Adherence to treatments for chronic rheumatic diseases is influenced by many factors, including the patient's belief in the development of adverse effects such as…Abstract Number: 1845 • ACR Convergence 2020
Long-Term Clinical Outcomes of Patients with Lupus Nephritis Treated with an Intensified B-Cell Depletion Protocol: A Matched Case-Control Study
Background/Purpose: Targeting B-cells remains an attractive option in Lupus Nephritis (LN) despite the negative results of RCTs.Methods: Sixty patients with active LN were included in…Abstract Number: 0163 • ACR Convergence 2020
Cost of Non-Persistence in the Treatment with Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors of Inflammatory Arthritis: A Propensity Score Matching Approach
Background/Purpose: Few studies have explored cost consequences of non-persistence in the treatment with Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors (SC-TNFi) in Inflammatory Arthritis (IA; rheumatoid arthritis…Abstract Number: 0238 • ACR Convergence 2020
Gestational Desire and Certolizumab Pegol in Patients with Chronic Inflammatory Rheumatic Disease. Preliminary Results of the GESTAMAD Cohort
Background/Purpose: INTRODUCTION The use of biological therapies during pregnancy has been contraindicated since the beginning of the use of these drugs. In recent years several…Abstract Number: 0366 • ACR Convergence 2020
Symptoms of Peripheral Arthritis Are Significantly Improved in Patients with Ankylosing Spondylitis Treated with Secukinumab
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease of the axial skeleton associated with pain, stiffness, and disability.1 Up to 66% of patients (pts)…Abstract Number: 0584 • ACR Convergence 2020
Total Cost of Care for Patients with Rheumatoid Arthritis
Background/Purpose: The range of medical costs associated with rheumatoid arthritis (RA) is, in part, related to the various treatment options. Treatment for RA focuses on…Abstract Number: 0806 • ACR Convergence 2020
Identification and Adjustment for Factors Associated with Clinical Response in Rheumatoid Arthritis Clinical Trials to Improve Comparisons of Treatment Efficacy
Background/Purpose: Numerous clinical trials have been published in rheumatoid arthritis (RA), but comparing efficacies of disease-modifying anti-rheumatic drugs (DMARDs) is complicated by a lack of…Abstract Number: 0881 • ACR Convergence 2020
Reduction of Anterior Uveitis Flares in Patients with Axial Spondyloarthritis During Certolizumab Pegol Treatment: 96-Week Results from the C-VIEW Study
Background/Purpose: Acute anterior uveitis (AAU) is the most common extra-articular manifestation in axial spondyloarthritis (axSpA), affecting up to 40% of patients and causing significant burden.1…Abstract Number: 1038 • ACR Convergence 2020
STAT1 and JAK2 Are the Most Appropriate Targets of JAK-inhibitor Therapy for Sarcoidosis: An In-silico Meta-nalysis
Background/Purpose: Our group was the first to contend that STAT1 mediated genes were expressed in sarcoidosis. Since that time, several other groups have found similar…Abstract Number: 1349 • ACR Convergence 2020
Guselkumab Provides Domain-Specific and Comprehensive Efficacy as Assessed Using Composite Endpoints in Patients with Active Psoriatic Arthritis
Background/Purpose: Guselkumab (GUS) is a human monoclonal antibody that specifically binds to the p19-subunit of IL-23. GUS has demonstrated efficacy across the various manifestations of…
- « Previous Page
- 1
- …
- 49
- 50
- 51
- 52
- 53
- 54
- Next Page »